These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

634 related articles for article (PubMed ID: 11152691)

  • 1. Evidence for a partially folded intermediate in alpha-synuclein fibril formation.
    Uversky VN; Li J; Fink AL
    J Biol Chem; 2001 Apr; 276(14):10737-44. PubMed ID: 11152691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes.
    Munishkina LA; Phelan C; Uversky VN; Fink AL
    Biochemistry; 2003 Mar; 42(9):2720-30. PubMed ID: 12614167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.
    Uversky VN; Li J; Fink AL
    J Biol Chem; 2001 Nov; 276(47):44284-96. PubMed ID: 11553618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
    Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
    J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease.
    Uversky VN; Li J; Fink AL
    FEBS Lett; 2001 Jul; 500(3):105-8. PubMed ID: 11445065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations.
    Uversky VN; Lee HJ; Li J; Fink AL; Lee SJ
    J Biol Chem; 2001 Nov; 276(47):43495-8. PubMed ID: 11590163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
    Li J; Uversky VN; Fink AL
    Neurotoxicology; 2002 Oct; 23(4-5):553-67. PubMed ID: 12428728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle.
    Uversky VN; Fink AL
    FEBS Lett; 2002 Jul; 522(1-3):9-13. PubMed ID: 12095610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dependence of alpha-synuclein aggregate morphology on solution conditions.
    Hoyer W; Antony T; Cherny D; Heim G; Jovin TM; Subramaniam V
    J Mol Biol; 2002 Sep; 322(2):383-93. PubMed ID: 12217698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethylamine-N-oxide-induced folding of alpha-synuclein.
    Uversky VN; Li J; Fink AL
    FEBS Lett; 2001 Nov; 509(1):31-5. PubMed ID: 11734201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease.
    Uversky VN; Li J; Bower K; Fink AL
    Neurotoxicology; 2002 Oct; 23(4-5):527-36. PubMed ID: 12428725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Forcing nonamyloidogenic beta-synuclein to fibrillate.
    Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
    Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of the conformation, fibrillation, and fibril morphologies of human brain α-, β-, and γ-synuclein proteins by the disaccharide chemical chaperone trehalose.
    Jain MK; Bhat R
    Biochim Biophys Acta Proteins Proteom; 2023 Sep; 1871(5):140932. PubMed ID: 37433401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro.
    Uversky VN; Yamin G; Souillac PO; Goers J; Glaser CB; Fink AL
    FEBS Lett; 2002 Apr; 517(1-3):239-44. PubMed ID: 12062445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein.
    Bertoncini CW; Jung YS; Fernandez CO; Hoyer W; Griesinger C; Jovin TM; Zweckstetter M
    Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1430-5. PubMed ID: 15671169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational insights into the role of α-strand/sheet in aggregation of α-synuclein.
    Balupuri A; Choi KE; Kang NS
    Sci Rep; 2019 Jan; 9(1):59. PubMed ID: 30635607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of protein-water interactions and electrostatics in alpha-synuclein fibril formation.
    Munishkina LA; Henriques J; Uversky VN; Fink AL
    Biochemistry; 2004 Mar; 43(11):3289-300. PubMed ID: 15023080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p25alpha Stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies.
    Lindersson E; Lundvig D; Petersen C; Madsen P; Nyengaard JR; Højrup P; Moos T; Otzen D; Gai WP; Blumbergs PC; Jensen PH
    J Biol Chem; 2005 Feb; 280(7):5703-15. PubMed ID: 15590652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.